Luminoah raises $25M to put tube feeding in your pocket
What's the deal? LuminoahDealroom has a profile for this one. Try Dealroom →, a Charlottesville, Virginia medical technology company, has raised a $25 million Series B led by Sandbox Clinical Ventures. The round includes $20 million in new equity and $5 million in converted notes.
Who else is in? Participants include the Blue Venture FundDealroom has a profile for this one. Try Dealroom →, GV, Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation FundDealroom has a profile for this one. Try Dealroom →, the American Gastroenterological Association GI Opportunity Fund, and existing backers.
What's the endgame? Luminoah is modernising enteral nutrition — tube feeding — a category it says has changed little in decades. The capital will fund wider distribution of its Luminoah Flow system, more manufacturing capacity, and development of Luminoah Intelligence, a clinician-facing data platform.
The product: Flow pairs a pocket-sized, rechargeable feeding pump and nutrition pouches with a connected mobile app, letting patients move during feeding instead of being tethered to a pole. When patients opt in, clinicians can review delivered nutrition through the data platform.
Why now? The round follows April 2026 FDA clearance and an early-access program with patients at healthcare institutions in the Pacific Northwest and Southeast. Founder and chief executive officer Neal Piper started the company after his son, Noah, relied on tube feeding during cancer treatment.
"For too long, families who depend on tube feeding have had to organise their lives around the pump. We built Luminoah so the technology could fit around their lives instead," Piper said.
What could go wrong? FDA clearance opens the door, but it does not guarantee reach. Medicare covers enteral pumps, yet wider access depends on supplier and health-system adoption — and Luminoah faces established suppliers such as Cardinal Health, whose Kangaroo OMNI pump is already on the market.
The signal: The $25 million is commercialisation backing for a long-neglected category, not yet proof of broad uptake. It bets that mobile, data-enabled feeding can displace an ageing standard of care — if distribution and reimbursement follow.
Read more: smb.magnoliastatelive.com
Image credit: Luminoah